SCIEX Introduces New Precise Mass Instrument, ZenoTOF 7600 System


System offers new capabilities for life science research and biotherapeutic development through novel ion fragmentation and increased sensitivity

FRAMINGHAM, Massachusetts, June 17, 2021– (BUSINESS WIRE) – SCIEX, a global leader in life science analytical technologies, introduces the ZenoTOF 7600 System, a new, precise mass LC-MS / MS instrument. The new system allows scientists to identify, characterize and quantify molecules better than ever by generating previously inaccessible data. This breakthrough will solve real analytical challenges and help advance the development of new precision diagnostics and biotherapeutics.

This press release features multimedia. View the full release here:

SCIEX introduces a new precise mass instrument – the ZenoTOF 7600 System. This system offers new capabilities for life science research and biotherapeutic development through new ion fragmentation and increased sensitivity. (Photo: Business Wire)

“Only a radical shift in innovation will achieve the ever more ambitious goals of scientists around the world. This new platform and this precise mass mindset has the power to change people’s perspectives and to have a profound impact on life. “
Joe Fox, President of SCIEX.

The ZenoTOF 7600 system includes the proprietary system Zeno trap and electron activated dissociation (EAD) fragmentation for the first time in a commercial instrument. The Zeno trap pulsation overcomes the traditional duty cycle challenges of orthogonal TOF technology, delivering up to 20 times the sensitivity and allowing routine detection of large scarce molecules. In combination, the adjustable EAD fragmentation ensures that new structural information can be extracted and quantified from various types of compounds – a capability that is not possible using only high resolution.

“The fact that we can now add alternative fragmentation to our existing workflows, and with higher sensitivity at the same time is truly extraordinary. It’s a real change in the way data is generated and in the biological information we can get. “
Matt Champion, Associate Professor, University of Notre Dame.

Extraordinary sensitivity associated with EAD fragmentation will push new boundaries in biomarker discovery and biopharmaceutical therapies

To advance the detection and treatment of disease, it is essential to understand how thousands of proteins, fats and metabolites in the body are regulated and modified. Biomarkers, the molecules that change when we are sick, are used by doctors as a “canary in the coal mine” warning system. So far, scientists have only scratched the surface of finding biomarkers. The ZenoTOF 7600 System will help scientists discover more and better biomarkers, bringing us closer to true precision medicine where the right medicine is delivered to the right patient at the right time.

Compared to previous systems, the ZenoTOF 7600 system can quantify up to 40% more protein and analyze samples 5 times faster for large biobank studies. In addition, EAD fragmentation brings new capabilities to understand how proteins are modified after translation – an important but difficult area in biomarker research.

“The ability to exactly match the kinetic energy for EAD optimizes MS / MS spectra and maximizes the precision of quantification. The use of the Zeno trap pulsation offers significant gains in sensitivity, further improving the utility of this approach for characterizing PTMs. “
Birgit Schilling, PhD, Associate Professor, Director of the Mass Spectrometry Center, The Buck Institute

The ZenoTOF 7600 System is transformational for lipidomics and can fully characterize an individual lipid from a single spectrum using EAD fragmentation. This will enable the discovery of new lipid markers for cancer and inflammatory diseases, precisely identifying and quantifying individual species, which was previously impossible.

“We have never been able to characterize up to the position of the double bond of lipid species, nor to identify the exact position of side chains. I see the ZenoTOF 7600 System as a really important advancement in being able to completely profile the lipidoma from the top down. “
James Cox, Associate Research Professor, University of Utah.

To bring relief new generation biopharmaceutical therapies to market quickly and safely, critical quality attributes must be analyzed quickly and comprehensively. For the first time, EAD fragmentation enables biopharmaceutical scientists to accurately detect and quantify protein glycosylation patterns and differentiate isomeric amino acids. Both are essential to ensure that therapies are safe and do not produce unwanted effects.

“As biopharmaceutical scientists seek to develop more complex and sophisticated biotherapeutics, the challenge of analysis also becomes more complex. The ability of EAD to regularly and accurately characterize these biologics will be a game-changer and make therapies available to patients much faster. “
Mani Krishnan, VP GM, CE & Biopharma at SCIEX

To learn more about the ZenoTOF 7600 system, go here.


SCIEX provides solutions for the precision detection and quantification of molecules, enabling our customers to protect and advance the well-being and safety of all. We have been a leader in the field of mass spectrometry for 50 years. Since the launch of the very first commercially successful triple quadrupole in 1981, we have developed revolutionary technologies and solutions that influence research and life-changing outcomes.

Today, as a member of the Danaher (NYSE: DHR) family of global life science and technology innovators, we continue to provide robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to respond quickly to environmental risks, better understand disease-related biomarkers, improve clinical patient care, bring relevant drugs to market faster, and maintain healthier and safer foods.

That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit

Let’s connect: Twitter, LinkedIn, Facebook and Instagram.

Advances in human well-being depend on the power of precise science.

The SCIEX clinical diagnostics portfolio is intended for in vitro diagnostic use. Rx only. Product (s) not available in all countries. For more information on availability, please contact your local sales representative or visit All other products are for research use only. Not for use in diagnostic procedures.

The trademarks and / or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and / or certain other countries (see

© 2021 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-13460-A.

View the source version on


Lulu Van Zandt
Manager, Brand, Public Relations and Social Media, SCIEX
[email protected]
+1 (508) 383-7163
M: +1 (508) 782-9484


Previous Christiana Music Program Persists During Pandemic To Provide Graduation Soundtrack | New
Next OlliOlli World is the fluorescent action platformer we all need right now